Status: Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection expansion part (Part 2).
Participants needed: 160
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: InSilico Medicine Hong Kong LimitedUpdated: Sep 16, 2026Locations: 10
Eligibility criteria
Male or female participants with age ≥18 years at the time of signing the inform... [+7]
Participants who have previously received a TEAD inhibitor. [+7]